Saturday, March 22, 2025 8:11:34 AM
Anavexs lead compound, 2-73, is small molecule that is easily manufactured. CEO Chris Missling once stated they already had enough 2-73 in stock-pile to dose (the whole of Manhattan) . It will be relatively cheap as well and most insurance's will cover it...cost is between $25-40k per year, depending on dose size. Alzheimer's is also a HUGE money maker the market potential is enormous vs. NWBO DCvax is very difficult to make and very expensive.
You also cant compare how AVXL is run vs NWBO. Missling vs Powers = Missling had a plan early on to raise cash and OS are only a bit above 82M vs 1.4B for NWBO. Anavex has a cash runway for 3+ years, vs day by day for NWBO. Missling is also very transparent and Company plans are communicated, in detail for the msot part to its shareholders and Wall Street. Missling also got Anavex added to the Russel, which was huge in terms of being added to Index and Mutual Funds. NWBO has poorly executed its business strategy, and I would argue they truly dont really have one, or if they do, they cant seem to execute it because they just dont have what it takes.
One thing is for sure...if Anavex receives approval from the current application for Alz in the EU...the stock is most likely going over $100. If NWBO receives approval for DCvax in the the UK, we may see .75-$1. The market is just to small to command much more than that in terms of market cap. No NICE appraisal and not FDA filing will be a HUGE detriment to SP upside.
Sorry for any typos, getting ready for my daughters hockey game.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
